ClinicalTrials.gg
TerminatedNCT03944707Updated Oct 11, 2021Results posted

Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients

A Phase 2 interventional study of LOU064 100 mg and Placebo in Asthma, sponsored by Novartis Pharmaceuticals. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 105 studies in Asthma by Novartis — 3 open to participants now, 5 under way, 2 of them phase 3. Asthma · Novartis.

Enrollment
56th of 97
76 · median 98
Started
2019
with 3 others
Phase 2
43 of 105
1 open now
Registered
92nd of 105
by date

Among the 105 studies in Asthma by Novartis, this one is the 56th largest by enrollment of the 97 interventional ones that give a count, is one of 4 that started in 2019, is one of 43 in phase 2, and was the 92nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 105 studies in Asthma by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Asthma by Novartis, or all of them as a file.
02

Study summary

This was a proof-of-concept study to evaluate the efficacy of LOU064 in patients with inadequately controlled asthma. All subjects were randomized with 3:2 ratio to receive LOU064 100 mg once daily or LOU064 matching placebo for 12 weeks with standard background therapy of budesonide 80 µg/formoterol 4.5 µg two inhalations twice a day (b.i.d).

Read the detailed description

This was a non-confirmatory, multi-center, randomized, placebo-controlled, subject- and investigator-blinded, parallel-group study to evaluate the efficacy and safety of LOU064 in patients with inadequately controlled asthma who were on a standardized background therapy of inhaled corticosteroid plus long acting beta-2 agonist (ICS/LABA).

The study included:

  • a Screening period of up to 2 weeks to assess eligibility.
  • a Run-in period of minimum 3 weeks and maximum 5 weeks where patients discontinued their current asthma therapy and were placed on budesonide 80 μg/formoterol 4.5 μg delivered by dry powder inhaler, two inhalations twice a day (b.i.d).
  • a Treatment period of 12 weeks. All subjects were randomized 3:2 to receive LOU064 100 mg once daily or placebo for 12 weeks with standard background therapy of budesonide 80 μg/formoterol 4.5 μg, two inhalations b.i.d.
  • a Follow-up period of 3 weeks following the last dose of study drug. Results from the interim analysis did not provide sufficient evidence of efficacy of LOU064 in inadequately controlled asthma and the sponsor decided to terminate early the study in April 2020. The median duration of exposure (12.0 weeks for LOU064 and 11.7 weeks for placebo) was close to the treatment target, as most of the subjects had completed treatment when the study was terminated.
03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • LOU064
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adult patients aged ≥ 18 to ≤ 70 years at screening.
  • Patients must weigh at least 40 kg to participate in the study, and must have a (BMI) \<35 kg/m2. BMI = Body weight (kg) / [Height (m)]2 at screening
  • Patients with a physician-diagnosed history of asthma (according to GINA 2018) for a period of at least 6 months prior to screening.
  • Patients who have been treated with:

    • Medium or high dose inhaled (ICS), or
    • ICS plus long-acting beta agonist (LABA), or
    • ICS plus leukotriene receptor antagonist (LTRA), or
    • ICS plus long-acting beta agonist (LABA) and long lasting muscarinic antagonist (LAMA) for at least 1 month prior to screening and on the same doses of the above mentioned medications over at least 2 weeks prior to start of the run-in period.
  • Post-bronchodilator reversibility of ≥ 12% and ≥ 200 mL at screening. If reversibility is not demonstrated at screening, then two additional attempts are permitted (one at the run-in visit and the last one during the run-in period between the run-in visit and baseline visit if needed)
  • Spirometry with pre-bronchodilator FEV1 ≥ 40% of predicted (at screening and baseline) and ≤ 85% of predicted at the baseline visit.
  • ACQ-5 score ≥ 1.5 at baseline visit
  • ≥ 80% compliance with peak expiratory flow measurement and recording of symptoms in the eDiary during the run-in period.

Exclusion criteria

Exclusion Criteria:

  • Patients who have had an asthma exacerbation requiring systemic , hospitalization, or emergency room visit within 6 weeks prior to screening or during the screening period.
  • Patients who have smoked or inhaled any substance other than asthma medications within the 6 month period prior to screening, or who have a smoking history of greater than 10 pack years (e.g. 10 pack years = 1 pack/day x 10 years or ½ pack/day x 20 years, etc.).
  • History of life-threatening asthma event such as significant hypercarbia (pCO2 > 45 mmHg), endotracheal intubation, non-invasive positive pressure ventilation (NIPPV), respiratory arrest, or seizure as a result of asthma.
  • Patients with chronic lung diseases other than asthma, including (but not limited to) , bronchiectasis, sarcoidosis, interstitial lung disease, cystic fibrosis, Churg-Strauss syndrome, allergic broncho-pulmonary aspergillosis, or clinically significant chronic lung diseases related to a history of tuberculosis or asbestosis.
  • History or current diagnosis of abnormalities indicating significant risk of safety for subjects participating in the study such as:

    • Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker
    • History of familial long syndrome or known family history of Torsades de Pointes
    • Resting heart rate (physical exam or 12 lead ECG) \< 50 bpm at screening
    • Resting QTcF ≥ 450 msec (male) or ≥ 460 msec (female) at screening or inability to determine the QTcF interval
    • Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of study
  • At screening and/or run-in period, any severe, progressive or uncontrolled, acute or chronic, medical or psychiatric condition, or other factors such as abnormal vital signs, ECG or physical findings, or clinically relevant abnormal laboratory values, that in the judgment of the investigator may increase the risk associated with study participation/treatment or may interfere with interpretation of study results, and thus would make the patient inappropriate for entry into or continuing the study.
  • Major surgery within 8 weeks prior to screening or surgery planned prior to end of study.
  • History of within 6 weeks prior to randomization or requirement to receive vaccinations at any time during the study.
  • Hematology parameters at screening:

    • : \< 10 g/dl
    • : \< 100 000/mm3
    • White blood cells: \< 3 000/mm3
    • Neutrophils: \< 1 500/mm3
  • Significant bleeding risk or coagulation disorders.
  • History of gastrointestinal bleeding, e.g. in association with use of Nonsteroidal Anti-Inflammatory Drug (NSAID).
  • Requirement for anti-platelet or anticoagulant medication (e.g., warfarin, or clopidogrel or Novel Oral Anti-Coagulant (NOAC)) other than acetylsalicylic acid (up to 100 mg/d).
  • History or presence of thrombotic or thromboembolic event, or increased risk for thrombotic or thromboembolic event.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    LOU064

    LOU064 100 mg once daily orally

    Drug: LOU064 100 mg

  • Placebo comparator
    Placebo

    Placebo once daily orally

    Drug: Placebo

Interventions

  • LOU064 100 mg once daily orally administered as two 50 mg capsules

  • DrugPlacebo

    Placebo once daily administered orally as capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pre-dose FEV1 at Week 12

    FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre-dose. The baseline pre-dose FEV1 is defined as the average of the FEV1 measurements performed 45 min and 15 min prior to dosing on Day 1. A positive change from baseline in pre-dose FEV1 is considered a favorable outcome. Change from baseline in pre-dose FEV1 was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*visit interaction and baseline pre-dose FEV1. A weakly informative prior was considered for the placebo response.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Maximum Observed Blood Concentrations (Cmax) of LOU064 at Steady State

    Pharmacokinetic (PK) parameters were calculated based on LOU064 blood concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1 ng/mL. Cmax was determined using non-compartmental methods.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85

  2. Time to Reach Maximum Blood Concentrations (Tmax) of LOU064 at Steady State

    PK parameters were calculated based on LOU064 blood concentrations determined by a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. Tmax was determined using non-compartmental methods.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85

  3. Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24h) of LOU064 at Steady State

    PK parameters were calculated based on LOU064 blood concentrations determined by a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. AUC0-24h was determined using non-compartmental methods. The linear trapezoidal rule was used for AUC0-24h calculation.

    Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85

  4. Change From Baseline in Asthma Symptom Questionnaire-5 Score (ACQ-5) at Week 12

    The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the overall ACQ-5 score is the mean of all 5 questions, therefore between 0 (totally controlled) and 6 (severely uncontrolled). The baseline values of ACQ-5 were collected at the baseline visit. A negative change from baseline in ACQ-5 is considered a favorable outcome. Change from baseline in ACQ-5 score was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*visit interaction and baseline ACQ-5 score. Non-informative priors were considered.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Mean Morning and Mean Evening Peak Expiratory Flow (PEF)

    PEF (Peak Expiratory Flow) is a person's maximum speed of expiration. All participants were instructed to record PEF twice daily before taking any medication using an electronic peak expiratory flow device (ePEF), once in the morning and once approximately 12 h later in the evening at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. For each day the best value in the morning and in the evening were considered and mean values on 4-week intervals were derived. The baseline values of PEF were the mean values in the run-in period. A positive change from baseline in PEF is considered a favorable outcome. Change from baseline in mean morning and mean evening PEF were analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*weeks interaction and baseline PEF values. Non-informative priors were considered.

    Time frame: Baseline, Weeks 9-12

  6. Change From Baseline in Number of Puffs of SABA Taken Per Day During the Treatment Period

    Participants were given a short acting β2-agonist (SABA; salbutamol, known also as albuterol) to use as rescue medication throughout the study along with an electronic diary (eDiary) to record rescue medication use. Participants recorded in the eDiary, once in the morning and once in the evening, the use of rescue medication (number of puffs of SABA taken in the previous 12 hours). The total number of puffs of SABA taken per day was calculated and the mean daily use of puffs of SABA over 12 weeks was derived. The baseline values of number of puffs of SABA taken per day were defined as the average from all non-missing records taken during the run-in period. A negative change from baseline is considered a favorable outcome. Change from baseline in number of puffs of SABA taken per day was analyzed using a Bayesian model, adjusting for effects of baseline SABA use, baseline FEV1, baseline asthma daytime symptom score and treatment. Non-informative priors were considered.

    Time frame: Baseline, 12 weeks

  7. Change From Baseline in Daytime and Nighttime Asthma Symptom Score

    Participants recorded asthma symptoms twice daily in the eDiary. Daytime asthma symptoms were assessed before bed and nighttime symptoms on awakening. * Daytime asthma symptom score included 4 questions. Overall score (0 to 6) was calculated as the average of the 4 questions with higher values indicating more asthma symptoms. * Nighttime asthma symptom score included 2 questions. Overall score (0 to 3.5) was calculated as the average of the 2 questions with higher values indicating more asthma symptoms. Mean values of both scores were calculated over 4-week intervals during the treatment period. The baseline values of both asthma symptoms scores were defined as the average score during the run-in period. A negative change from baseline is a favorable outcome. Change from baseline in daytime and nighttime asthma symptom score were analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*weeks and baseline scores. Non-informative priors were considered.

    Time frame: Baseline, Weeks 9-12

07

Results

Posted Apr 27, 2021

Participant flow

Participants took part in 19 investigative sites in 5 countries.

Participant flow — Overall Study
MilestoneLOU064Placebo
Started4729
Pk analysis set330
Pd analysis set4729
Completed3519
Not completed1210
Withdrew: Adverse event02
Withdrew: Study terminated by sponsor127
Withdrew: Subject decision01

Outcome measures

PrimaryChange From Baseline in Pre-dose FEV1 at Week 12

FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre-dose. The baseline pre-dose FEV1 is defined as the average of the FEV1 measurements performed 45 min and 15 min prior to dosing on Day 1. A positive change from baseline in pre-dose FEV1 is considered a favorable outcome. Change from baseline in pre-dose FEV1 was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*visit interaction and baseline pre-dose FEV1. A weakly informative prior was considered for the placebo response.

Time frame:
Baseline, Week 12
Reported as:
Mean · liters
Change From Baseline in Pre-dose FEV1 at Week 12
litersLOU064Placebo
Change From Baseline in Pre-dose FEV1 at Week 120.105 ± 0.04940.075 ± 0.0497
Statistical analysis
  • LOU064 vs Placebo · Bayesian model for repeated measures · p = 0.6643 (Probability LOU064 better than placebo) · Mean difference (net): 0.030 · 80% CI -0.060 to 0.119Posterior mean difference (LOU064 - placebo) and 80% credible interval are presented.
SecondaryMaximum Observed Blood Concentrations (Cmax) of LOU064 at Steady State

Pharmacokinetic (PK) parameters were calculated based on LOU064 blood concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1 ng/mL. Cmax was determined using non-compartmental methods.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85
Reported as:
Mean · ng/mL
Maximum Observed Blood Concentrations (Cmax) of LOU064 at Steady State
ng/mLLOU064Placebo
Day 15239 ± 152—
Day 85222 ± 142—
SecondaryTime to Reach Maximum Blood Concentrations (Tmax) of LOU064 at Steady State

PK parameters were calculated based on LOU064 blood concentrations determined by a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. Tmax was determined using non-compartmental methods.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85
Reported as:
Median · hours (hr)
Time to Reach Maximum Blood Concentrations (Tmax) of LOU064 at Steady State
hours (hr)LOU064Placebo
Day 151.00 (0.483 to 2.00)—
Day 851.00 (0.500 to 3.00)—
SecondaryArea Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24h) of LOU064 at Steady State

PK parameters were calculated based on LOU064 blood concentrations determined by a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. AUC0-24h was determined using non-compartmental methods. The linear trapezoidal rule was used for AUC0-24h calculation.

Time frame:
pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85
Reported as:
Mean · hr*ng/mL
Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24h) of LOU064 at Steady State
hr*ng/mLLOU064Placebo
Day 15471 ± 285—
Day 85517 ± 342—
SecondaryChange From Baseline in Asthma Symptom Questionnaire-5 Score (ACQ-5) at Week 12

The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the overall ACQ-5 score is the mean of all 5 questions, therefore between 0 (totally controlled) and 6 (severely uncontrolled). The baseline values of ACQ-5 were collected at the baseline visit. A negative change from baseline in ACQ-5 is considered a favorable outcome. Change from baseline in ACQ-5 score was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*visit interaction and baseline ACQ-5 score. Non-informative priors were considered.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on scale
Change From Baseline in Asthma Symptom Questionnaire-5 Score (ACQ-5) at Week 12
score on scaleLOU064Placebo
Change From Baseline in Asthma Symptom Questionnaire-5 Score (ACQ-5) at Week 12-0.95 ± 0.133-0.86 ± 0.164
Statistical analysis
  • LOU064 vs Placebo · Bayesian model for repeated measures · p = 0.6609 (Probability LOU064 better than placebo) · Median difference (net): -0.09 · 80% CI -0.35 to 0.18Posterior mean difference (LOU064 - placebo) and 80% credible interval are presented.
SecondaryChange From Baseline in Mean Morning and Mean Evening Peak Expiratory Flow (PEF)

PEF (Peak Expiratory Flow) is a person's maximum speed of expiration. All participants were instructed to record PEF twice daily before taking any medication using an electronic peak expiratory flow device (ePEF), once in the morning and once approximately 12 h later in the evening at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. For each day the best value in the morning and in the evening were considered and mean values on 4-week intervals were derived. The baseline values of PEF were the mean values in the run-in period. A positive change from baseline in PEF is considered a favorable outcome. Change from baseline in mean morning and mean evening PEF were analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*weeks interaction and baseline PEF values. Non-informative priors were considered.

Time frame:
Baseline, Weeks 9-12
Reported as:
Mean · liters/minute
Change From Baseline in Mean Morning and Mean Evening Peak Expiratory Flow (PEF)
liters/minuteLOU064Placebo
Change from baseline in mean morning PEF-2.4 ± 4.30-2.6 ± 5.59
Change from baseline in mean evening PEF-9.7 ± 5.58-6.3 ± 7.23
Statistical analysis
  • LOU064 vs Placebo · Bayesian model for repeated measures · p = 0.5107 (Probability LOU064 better than placebo) · Mean difference (net): 0.1 · 80% CI -9.0 to 9.1Posterior mean difference (LOU064 - placebo) and 80% credible interval are presented.
  • LOU064 vs Placebo · Bayesian model for repeated measures · p = 0.3611 (Probability LOU064 better than placebo) · Mean difference (net): -3.4 · 80% CI -15.2 to 8.1Posterior mean difference (LOU064 - placebo) and 80% credible interval are presented.
SecondaryChange From Baseline in Number of Puffs of SABA Taken Per Day During the Treatment Period

Participants were given a short acting β2-agonist (SABA; salbutamol, known also as albuterol) to use as rescue medication throughout the study along with an electronic diary (eDiary) to record rescue medication use. Participants recorded in the eDiary, once in the morning and once in the evening, the use of rescue medication (number of puffs of SABA taken in the previous 12 hours). The total number of puffs of SABA taken per day was calculated and the mean daily use of puffs of SABA over 12 weeks was derived. The baseline values of number of puffs of SABA taken per day were defined as the average from all non-missing records taken during the run-in period. A negative change from baseline is considered a favorable outcome. Change from baseline in number of puffs of SABA taken per day was analyzed using a Bayesian model, adjusting for effects of baseline SABA use, baseline FEV1, baseline asthma daytime symptom score and treatment. Non-informative priors were considered.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · puffs of SABA
Change From Baseline in Number of Puffs of SABA Taken Per Day During the Treatment Period
puffs of SABALOU064Placebo
Change From Baseline in Number of Puffs of SABA Taken Per Day During the Treatment Period-0.192 ± 0.0946-0.059 ± 0.1224
Statistical analysis
  • LOU064 vs Placebo · Bayesian model · p = 0.8022 (Probability LOU064 better than placebo) · Mean difference (net): -0.133 · 80% CI -0.336 to 0.071Posterior mean difference (LOU064 - placebo) and 80% credible interval are presented.
SecondaryChange From Baseline in Daytime and Nighttime Asthma Symptom Score

Participants recorded asthma symptoms twice daily in the eDiary. Daytime asthma symptoms were assessed before bed and nighttime symptoms on awakening. * Daytime asthma symptom score included 4 questions. Overall score (0 to 6) was calculated as the average of the 4 questions with higher values indicating more asthma symptoms. * Nighttime asthma symptom score included 2 questions. Overall score (0 to 3.5) was calculated as the average of the 2 questions with higher values indicating more asthma symptoms. Mean values of both scores were calculated over 4-week intervals during the treatment period. The baseline values of both asthma symptoms scores were defined as the average score during the run-in period. A negative change from baseline is a favorable outcome. Change from baseline in daytime and nighttime asthma symptom score were analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*weeks and baseline scores. Non-informative priors were considered.

Time frame:
Baseline, Weeks 9-12
Reported as:
Mean · score on scale
Change From Baseline in Daytime and Nighttime Asthma Symptom Score
score on scaleLOU064Placebo
Change from baseline in daytime asthma symptom score-0.225 ± 0.0962-0.175 ± 0.1237
Change from baseline in nighttime asthma symptom score-0.120 ± 0.0488-0.195 ± 0.0651
Statistical analysis
  • LOU064 vs Placebo · Bayesian model for repeated measures · p = 0.6312 (Probability LOU064 better than placebo) · Mean difference (net): -0.050 · 80% CI -0.251 to 0.149Posterior mean difference (LOU064 - placebo) and 80% credible interval are presented.
  • LOU064 vs Placebo · Bayesian model for repeated measures · p = 0.1752 (Probability LOU064 better than placebo) · Mean difference (net): 0.075 · 80% CI -0.028 to 0.180Posterior mean difference (LOU064 - placebo) and 80% credible interval are presented.

Adverse events

Collected over From first dose of study treatment until last dose of study treatment plus 30 days post treatment, up to Day 115.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LOU0640/47 (0%)0/47 (0%)8/47 (17%)
Placebo0/29 (0%)0/29 (0%)10/29 (34.5%)
Most frequent other events
Most frequent other events
EventLOU064Placebo
NasopharyngitisInfections and infestations4/476/29
Upper respiratory tract infectionInfections and infestations4/474/29
AsthmaRespiratory, thoracic and mediastinal disorders0/472/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)LOU064PlaceboTotal
Mean49.2 ± 10.9653.2 ± 10.4050.7 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)LOU064PlaceboTotal
Female282250
Male19726
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LOU064PlaceboTotal
Caucasian422769
Black426
Asian101
08

Study locations

19 sites
  • Novartis Investigative Site
    Denver, Colorado 80230, United States
  • Novartis Investigative Site
    North Dartmouth, Massachusetts 02747, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Raleigh, North Carolina 27607, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1056ABJ, Argentina
  • Novartis Investigative Site
    Caba, Buenos Aires C1425BEN, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000DBS, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000JKR, Argentina
  • Novartis Investigative Site
    Berlin, 10787, Germany
  • Novartis Investigative Site
    Berlin, 12159, Germany
  • Novartis Investigative Site
    Frankfurt, 60596, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Hannover, 30173, Germany
  • Novartis Investigative Site
    Biaystok, 15-430, Poland
  • Novartis Investigative Site
    Grudziadz, 86-300, Poland
  • Novartis Investigative Site
    Krakow, 30033, Poland
  • Novartis Investigative Site
    Poznan, 60 823, Poland
  • Novartis Investigative Site
    Saint-Petersburg, 196143, Russian Federation
  • Novartis Investigative Site
    Ulyanovsk, 432063, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Apr 2020, 9 months.

Results were first posted in Apr 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2019
First posted
May 9, 2019
StartActual
Jul 18, 2019
Primary completionActual
Apr 27, 2020
CompletionActual
Apr 27, 2020
Results first posted
Apr 27, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03944707
Responsible party
Sponsor
First posted
May 9, 2019
Start date
Jul 18, 2019
Primary completion
Apr 27, 2020
Completion
Apr 27, 2020
Results posted
Apr 27, 2021
Last update
Oct 11, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion